Molecular Pathogenesis of Philadelphia-Positive Chronic Myeloid Leukemia – is it all BCR-ABL?
Journal:
Current Cancer Drug Targets
Volume:
11
Page:
3-19
Author(s):
H. Rumpold and G. Webersinke
Current Treatment Concepts of CML
Journal:
Current Cancer Drug Targets
Volume:
11
Page:
31-43
Author(s):
A. A. Leitner, A. Hochhaus and M. C. Muller
Current Treatment Concepts of Philadelphia-Negative MPN
Journal:
Current Cancer Drug Targets
Volume:
11
Page:
44-55
Author(s):
D. Wolf, J. Rudzki and G. Gastl
Targeting of Leukemia-Initiating Cells to Develop Curative Drug Therapies: Straightforward but Nontrivial Concept
Journal:
Current Cancer Drug Targets
Volume:
11
Page:
56-71
Author(s):
P. Valent
Immunotherapy for Myeloproliferative Neoplasms (MPN)
Journal:
Current Cancer Drug Targets
Volume:
11
Page:
72-84
Author(s):
Susanne Hofmann, Anna Babiak and Jochen Greiner
Electrochemical Indicators for DNA Electroanalysis
Journal:
Current Analytical Chemistry
Volume:
7
Page:
51-62
Author(s):
Elena E. Ferapontova
Novel Rational Drug Design Strategies with Potential to Revolutionize Malaria Chemotherapy
Journal:
Current Medicinal Chemistry
Volume:
18
Page:
113-143
Author(s):
F. W. Muregi, P. G. Kirira and A. Ishih
Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Journal:
Anti-Cancer Agents in Medicinal Chemistry
Volume:
11
Page:
109-132
Author(s):
Caroline Nunes-Xavier, Carlos Roma-Mateo, Pablo Rios, Celine Tarrega, Rocio Cejudo-Marin, Lydia Tabernero and Rafael Pulido
Promotion of Apoptosis in Cancer Cells by Selective Purine-Derived Pharmacological CDK Inhibitors: One Outcome, Many Mechanisms
Journal:
Current Pharmaceutical Design
Volume:
17
Page:
256-271
Author(s):
Jozefa Wasierska-Gadek and Margarita Maurer
Omacetaxine as an Anticancer Therapeutic: What is Old is New Again
Journal:
Current Pharmaceutical Design
Volume:
17
Page:
59-64
Author(s):
Meir Wetzler and David Segal